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Methods: Five hospitals in New York City contributed prospectively defined data elements 
on 10,847 patients undergoing porcutaneous coronary intervention between January 1, 
1998 and October 31, 1999. We analyzed the outcomes of 1112 patients from this data- 
base who underwent PPTCA for AMI with or without GPI treatment. 
Reeulte: Of the 1112 patients undergoing PPTCA for AMI, 336 (30%) were treated with 
GPI. GPl-treated patients were younger (61 years vs. 63 years, P=0.02), more often male 
(77% vs. 70%, P=0.02)and less often hypertensive (57% vs. 66%, P=0.003)compared to 
patients not treated with GPL There were no significant differences with regard to diabetes, 
congestive heart failure, previous MI or prior bypass surgery between GPI-treated and 
untreated patients. Mean ejection fraction (49% vs, 47%) did not differ between groups. 
Hemodynamic instability was more common in the GPI-treatsd patients (17% vs. 9%, 
P<0.001). Patients treated with GPI were less likely to receive a stent (78% vs. 88%, 
P<0.001) than untreated patients. Procedural success was 98% in the GPI group and 97% 
for untreated patients (P=NS). The rates of post-procedure stroke, abrupt closure and stent 
thrombosis were equal in both groups. Pre-prooedure CK levels were similar in both 
groups (681 U/I- vs. 663 U/L, P=NS). The proportion of GPI-treated and untreated patients 
with CK levels >5 times normal at 8 (40% vs. 45%, P=NS) and 24 hours (37% vs. 34%, 
P=NS) were also similar. In-hospital mortality was 3% in the GPI-treated group compared 
to 2.2% in the untreated group (P=NS). After adjustment for differences in baseline oharac- 
tsristics, the risk of in-hospital mortality remained unchanged by GPI treatment. 
Conclusion: GPI do not appear to have an effect on in-hospital outcomes following 
PPTCA for AMI. 
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1124-27 TENAX-XR a:SiC-H Coated Stent  Versus  Noncoatsd  
Stents  in 485 Patients With Acute Coronary Syndrome: 
9- and 18-Month Follow-Up: The TRUST Trial 
Christian Harem, on behalf of the TRUST Investigator's, CorTrial GmbH, Berlin, 
Germany. 
The TENAX-XR stent is a stainless steel stent covered by a thin layer of silicon carbide 
by plasma enhanced chemical vepour deposition. This coating markedly reduces cellular 
aggregation. TRUST is a multi-centre randomized trial investigating the efficacy of this 
device in Unstable Angina Braunwald IIb-IIIb patients. All patients were clinically 
assessed upon discharge, 1, 3, 6, 9 and 18 months. All patients received the usual pre- 
medication, in addition Aspirin and Clopidogrel (or Ticlopidin) was given for 30 days. 
GPIIb / Ilia antagonists were given at the discretion of the operator, in only 2.1%. Suc- 
cessrete for the TENAX-XR was 91%, in the reference group 87%. There were no deaths 
during the initial hospitalization; one myocardial Infarction occurred in the reference 
group, one PCI was required in each of the two groups. The primary endpoint, combina- 
tion of a death, AMI and ischemia indicated target lesion revascularisation was virtually 
identical at 6 and 9 month in the Braunwald lib group (9.6 %). However, in the Breunwald 
IIIb group there was a significant difference: TENAX-XR at 4.7 % vs 15.3 % in the refer- 
ence group (p=0.02) with this tendency continuing at 9 month and 18 month follow-up. 
Concluelon. Early PCI (0.4 + 1.1 day after admission for severe symptoms) can be car- 
ded out at an extremely low risk with standard anti-thrombotic therapy including ASA and 
Clopidogrel. lib/Ilia GP inhibitors apparently are not required. These data support the 
experimental data obtained with the silicon carbide coating. They suggest that with the 
initial 30 day treatment of ASA + Clopidogrei, the continued beneficial action of the coat- 
ing leads to a marked reduction of MACE at 6, 9 and 18 months. 
1124-28 807CC Genotype  of  the  Platelet  Gp la Could Represent a 
Protective Factor for Recurrences of Acute Coronary 
Events in Acute Coronary Syndromes 
Antonio Maria Leone. I. Casorelli, F, Burzotta, K. Paciaroni, A, Sciahbasi, V, De Stefano, 
G. Leone, F, Andreotti, A. Maseri, Universita Cattolica de/Sacro Cuore, Rome, Italy. 
Introduction: Glycoprotein la/lla is an heterodimedc membrane complex that mediates 
platelet adesion to collagen, inducing platelets to aggregate. Recently a functional 
genetic polymorphism of the ta subunit has been reported, consisting in a C807T transi- 
tion (linked with A873G), associated with a variable expression of the platelet surface 
receptor. The lower receptor density of 807CC genotype may predispose to a hypocoag- 
ulable state and, then, to a reduction of the recurrence risk of Acute Coronary Events 
(ACE) in Acute coronary Syndromes (ACS). Methods: we enrolled 88 patients (pts), 61 
with Acute Myocardial Infarction (AMI) and 27 with severe Unstable Angina (UA) as the 
first manifestation of disease occuring before 65 years of age, following them until 120 
months. Results: 40 pts (23 AMI, 17 UA; 7 females, 52 ± 3 years) showed the 807 CC 
genotype, 38 pts (28 AMI, 10 UA; 7 females, mean age 53 years) the 807CT genotype, 
10 pts (10 AMI; all males, mean age 54) the 8071"T genotype. Pts with 807CC genotypo 
showed a free-event median survival significantly longer than pts with 807CT or 807 1-1" 
geootype either in the entire group (64 months vs 44 months; p<0.05; Ask rafio=0.4889 
95%CI 0.25-0.99 ) and especially in the 61 pts with AMI. (p<0.03; risk ratio=0.35, 95%CI 
0.1817-0,9159). Finally no statistically significant difference was found between 807CT 
and 807 CT genotypes. Conclusions: these data suggest that in the ACS, pts with 807CC 
genotype, characterized by a lower collagen receptor density on platelet membrane, 
could have a lower recurrence risk of ACE compared to 807T allele carriers. 
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1124-29 Hepar in/PF4 Complex Antibodies in Pat ients  With 
Unstable Angina: Evaluation of Cardiac Thrombotic 
Events in 24 Months of Follow-Up 
Anna Vittoria Mattioli, Leonardo Fontanesi, Lorenzo Bonetti, Roberto Vandeili, Giorgio 
Mattioli, University of Modena and Reggio E., Modena, /ta/)~ 
Background. Unfractionated heparin (UH) and low molecular weight heparin (LMWH) 
play an important role in standard therapy of unstable angina. The treatment with UH can 
induce in a variable number of patients antibodies against hepadn/PF4 complex. The aim 
of the present study is to evaluate cardiac events in 24 months follow-up in patients (pts) 
treated with UH or LMWH. 
Methods. We evaluated 114 pts (71 men, of mean age 68 -+ 11 years, range 46-85 years) 
admitted to our facility with unstable angina. They were randomized in two groups: group 
A treated with UH and group B treated with LMWH. An immunoassay ELISA test was 
used to detect anti-hepadn/PF4 antibodies. Blood samples were taken at baseline and 
on the 7th and the 40th day. The mean follow-up period was of 21.5 ± 15.2 months, 
(group B 23.2 _+ 17.8 months and group A 19.68 ± 14.8 months). End-points were: acute 
myocardial infarction, angina, need for revascularization, stroke and death for all causes. 
Statistical analysis included a Kaplan and Maier analysis and the Log Rank Test. 
Results. The frequency of a positive ELISA did not vary with patient's age or gender. In 
group A 55% pts were positive for heparin/PF4 antibodies at ELISA on day 40. In group 
B none pts tested positive for beparin/PF4 antibodies. Group A was divided in 2 sub- 
groups according to presence (group AAc+) or absence (group AAc-) of antibodies. We 
reported a significant difference in cumulative vents between group B and group AAc+ 
(Log rank=7,57; p=0,005 Fig.l). No difference was observed between group B and group 
AAc- (Log rank=0.22; p=0,6382). 
Conclusions. Pts treated with LMWH had a better prognosis compared with pts treated 
with UH. We observed that the difference exists only between pts that developed anti- 
bodies, suggesting a link between anti-heparin/PF4 antibodies end thrombotic cardiac 
events. 
1124-30 Risk of  lechemic  Events  Can Be Predicted by 
Ang ioecop ic  Eva luat ion of  Ye l low Plaques 
Tomohito Ohtani, Yasunori Ueda, Masahiko Shimizu, Nobuhiko Kondou, Atsushi 
Hirayama, Kazuhisa Kodama, Osaka Police Hospital, Osaka, Japan. 
Background: Elevated C-reactive protein (CRP) has been proved a marker of increased 
risk of atherothrombotic linical events. Disruption of lipid-rich plaque, which is detected 
by angiscopy as yellow plaque, is regarded as one of the major mechanisms of acute 
coronary syndrome and atherosclerosis progression. Therefore, we examined the rela- 
tion between ischemic events after PCI with CRP elevation or with progression of yellow 
plaque formation. 
Methods: Angioscopic evaluation was performed in 131 patients when they received 
PCI. The number of yellow plaques in a coronary artery was counted by angioscopy. 
Serum concentrations of CRP (N < 0.2 mg/l) were measured on admission. They were 
followed up for new ischemio events, i.e., acute myocardiar infarction (AMI) and unstable 
or stable angina, for 4.9i-0.8 years. The recurrence of angina due to restenosis was not 
counted as new ischemic event. 
Results: New ischemic events were documented in 19 patients (AMI occurred in 4 
patients, and effort angina in 15 patients). Although there was no relationship (p=0.101) 
between serum CRP and the occurrence of ischemic events, the patients who suffered 
new ischemic event had more yellow plaques (2.8±1.3 vs. 1.9-/0.9; p=0.049) than those 
who did not. The incidence of AMI (13.1% vs, 0.14%, p=0.015) and of new ischemic 
events (39.1% vs. 13.9%, p=0.008) were significantly higher in the patients who had >2 
yellow plaques than those who had <2 yellow plaques in the coronary artery that had cul- 
prit lesion. 
Conclusions: The risk of suffering new ischemic events during 5-years after PCI can be 
evaluated by counting the number of yellow plaques in a coronary artery by angioscopy. 
1124-45 Acute Myocardial In farct ion in HIV- Infectsd Pat ients  
Shlomi Matetzkv, Eric Daar, Michelle Domingo, Bojan Cercek, Cedars Sinai Medical 
Center, Los Angeles, California. 
Background: Recent reported series of patients suggested that HIV-infectsd patients are 
at an increased risk of premature coronary artery disease. However, the mechanisms are 
not fully understood and there is little information regarding the clinical outcome of acute 
coronary syndrome in these patients. 
Methods: We compared the characteristics and long-term course of 24 consecutive HIV- 
infected patients with AMI, and 48 age- and gender- matched non-HIV patients. 
Results: The mean age was 47±49 and 88% were males in both groups. Twenty-two 
HIV-infected patients (92%) were receiving an anti-retroviral drug, 17 (71%) protease 
inhibitors (Pl), and 13 (54%) statins. HIV-infected patients had lower cholesterol (175±49 
vs 210±48, p=0.013), LDL (104±40 vs 136±44, p=0.011) and HDL values (32±9.7 vs 
40±9.9, p=0,005) Otherwise there were no significant differences in risk factors for CAD. 
Angiographically, there were no significant differences in the incidence of multi-vessel 
CAD (76% vs 54%, p=0.15), and revasculadzation (83% vs 94%, p=0.31). Both HIV- 
infected and control patients had a relatively benign in-hospital course with no deaths or 
reinfarctions. There was also no significant difference in the indices of myocardial dam- 
age (peak troponin, LVEF). In a mean follow-up of 15 months, HIV-infected patients had 
higher incidence of re-infarction (20% vs 4%, p=0.07), recurrent coronary event (45% vs 
11%, p=0.007), and recurrent acute atherothrombotic event (cardiovascular death, reinf- 
aretion, acute cerebro- or peripheral vascular event 30% vs 4.4%, p=0.008). Among 
patients who underwent PTCA, HIV-infected patients had higher incidence of target ves- 
sel revascularization (TVR) (43% vs 10.5%, p=0.016). TVR was particularly evident in- 
patients with increased viral load, irrespective of PI therapy. In HIV-infected patients, 
treatment with PI was not assooiated with higher cholesterol, LDL, or triglycedde levels, 
